Keurig Dr Pepper Inc. will announce its financial results for the third quarter ending September 30, 2026, on November 3 before the market opens. The company will hold a conference call at 8:00 AM ET the same day, hosted by CEO Tim Cofer and CFO Anthony DiSilvestro, to discuss the results. Investors can access the call via phone or webcast, with a replay available until November 17. This earnings report will provide insights into the company's performance across its beverage and coffee brands.
Keurig Dr Pepper's upcoming Q3 2026 results come as 16 of 51 Consumer Staples-sector US stocks tradable on Pluang rose while 35 fell. For readers following this sector, here is Pluang's market snapshot as of Oct 02, 2026 02:41 WIB: Kraft Heinz Co (KHC) traded at USD 22.34 with a 1-day change of -1.69% and 100% buy order activity; General Mills, Inc. (GIS) was at USD 31.62, down 1.68%, also with 100% buy order activity; Diageo plc (DEO) stood at USD 84.22, down 1.61%, with a typical hold time of 64 days.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
